Background: Our study seeks to clarify the extent of differences in analytical results, from a clinical perspective, among 4 leading technologies currently used in clinical reference laboratories for the analysis of LDL subfractions: gradient gel electrophoresis (GGE), ultracentrifugation-vertical auto profile (VAP), nuclear magnetic resonance (NMR), and tube gel electrophoresis (TGE). Methods: We collected 4 simultaneous blood samples from 40 persons (30 males and 10 females) to determine LDL subclasses in 4 different clinical reference laboratories using different methods for analysis. LDL subfractions were assessed according to LDL particle size and the results categorized according to LDL phenotype. We compared results obtained from the different technologies. Results: We observed substantial heterogeneity of results and interpretations among the 4 methods. Complete agreement among methods with respect to LDL subclass phenotyping occurred in only 8% (n ‫؍‬ 3) of the persons studied. NMR and GGE agreed most frequently at 70% (n ‫؍‬ 28), whereas VAP matched least often. Conclusions: As measurement of LDL subclasses becomes increasingly important, standardization of methods is needed. Variation among currently available methods renders them unreliable and limits their clinical usefulness.
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Cardiovascular disease (CVD) 3 is characterized by the progressive appearance of fibro-fatty plaque (atheroma) along the vascular endothelium and the coronary arteries (1 ) . Early studies established that increased LDLcholesterol (LDL-C) concentrations accelerated plaque formation (2 ) . However, increased LDL-C concentrations do not completely predict plaque formation. Chemical modification of polyunsaturated fats carried in the LDL particle can greatly enhance its atherogenicity (3) (4) (5) .
Considerable heterogeneity exists in the physical properties (size and density) of LDL lipoprotein particles among groups of individuals (5 ) . Moreover, many CVD patients do not have increased LDL-C (1, 6 -8 ) . These ambiguities were partially resolved by the demonstration of a significant association between LDL subclasses, intermediate-density lipoprotein, increased plasma triglyceride concentrations, and low plasma HDL-cholesterol (9 ) . Adjustment for triglycerides, however, reduced the relative risk of myocardial infarction from 3 to 1.5 (95% confidence interval, 0.8 -3.2), indicating a close association between certain types of LDL particle and plasma triglyceride concentration. Those investigators (9 ) grouped patients into type A and type B LDL patterns on the basis of the size/density distribution of the LDL particle subclasses (10 -15 ) .
There are now suggestions that environmental and metabolic factors can influence atherogenic profiles and potentially shift a type B LDL pattern toward a type A LDL pattern (16 -18 ) . Thus, clinical use of the LDL profile as a basis for dietary counseling, lifestyle adjustments, and the effectiveness of pharmacologic agents in reducing the risk of CVD could help guide potential treatment interventions (19 ) .
Analytical ultracentrifugation is considered to be the benchmark for determining lipoprotein subfractions (20, 21 ) . However, other methodologies have also been used, including nondenaturing gradient gel electrophoresis (GGE) (20, 22 ) , density gradient ultracentrifugation (23 ) , and nuclear magnetic resonance (NMR).
Unfortunately, the estimated number of LDL subfractions is method dependent. Therefore, different methods may classify a patient's LDL particle type differently, making comparisons only tenuous and extrapolation to patient results difficult. The increasing clinical use of these newer technologies makes accurate and consistent patient classification by different laboratories crucial. To evaluate the performance of these new technologies for determining LDL subclasses and their effects on patient classification based on LDL subclass pattern, we conducted this comparison study.
Materials and Methods
Blood samples were collected into BD Vacutainer Tubes (BD Diagnostics) from 40 apparently healthy persons (30 males) 23 to 61 years of age. Serum and EDTA-plasma were kept at ambient temperature and separated within 2 h by centrifugation at 1430g for 15 min at 4°C, aliquoted, and then frozen at Ϫ70°C. Samples from each person were sent to 4 different laboratories for analysis. A portion of each serum sample was shipped frozen to Atherotech (Birmingham, AL), and another portion was retained frozen at our laboratory (Kronos Science Laboratories, Phoenix, AZ) for LDL subfractionation using the Lipoprint TM system (Quantimetrix). EDTA-plasma samples were shipped frozen for analysis to Liposcience (Raleigh, NC) and Berkley HeartLab (Alameda, CA). Each of the laboratories used a different method for LDL fractionation and LDL particle size determination (9 ).
method 1: gge
To assess LDL subfractions, Berkeley Heartlab uses LDL Segmented Gradient Gel Electrophoresis (LDL-S 3 GGE TM ). This technique separates LDL particles into 7 LDL subfractions based on particle size and shape (20, 22, 23 
method 2: ultracentrifugation-vertical auto profile
The Vertical Auto Profile-II, or VAP-II test (Atherotech), is derived from density gradient ultracentrifugation (24, 25 ) . The VAP-II generates a series of absorbance curves from which proprietary software produces 6 LDL subclasses labeled as LDL1 (most buoyant) through LDL6 (most dense). LDL1 and LDL2 comprise pattern type A and LDL3 and LDL4 comprise pattern type B (26 
) (28 ).
This technology does not measure the LDL particle size directly, but estimates LDL particle size by comparing particle electrophoretic mobility with the electrophoretic mobilities of particles of known sizes. The total cholesterol of the sample must be measured independently of the Lipoprint system. The Lipoprint report contains the patient's scan and the cholesterol concentration within each of the fractions based on retardation factor (R f ), which correspond to each of the LDL subfractions. The scan contains 7 possible LDL subfractions.
statistical analysis
For across-method comparisons, we used a repeatedmeasures ANOVA and pairwise contrasts. Significance was established with the Bonferroni adjustment. When the sphericity assumption was in question, the Greenhouse-Geisler adjustment for the degrees of freedom was used to determine overall statistical significance. We used the intraclass correlation coefficient to establish the agreement among the within-subject data across laboratory values. When possible, the distribution of cholesterol contained in LDL and the estimates for LDL particle sizes for each laboratory were evaluated by use of boxplots. The cholesterol, triglyceride, and major lipoprotein cholesterol values were taken from the patient reports obtained from each method. Because this report primarily focuses on LDL particle characteristics and their use for LDL phenotype classification, HDL subfractions were not included in this analysis. All LDL particle sizes were converted to nanometers for comparisons across methods. A value of 5 nm was added to the NMR estimates of LDL particle size per the laboratory's statement included in the 
Results
The distribution of LDL phenotypes among the 40 persons for each method is shown in Fig. 1 Patient classification data for each of the 4 methods are shown in Table 1 . Complete agreement among the laboratory methods occurred in 3 (persons 2, 5, and 11) of 39 persons (ϳ8%). NMR matched other methods to a greatest extent (marginal totals) and VAP matched the least. NMR and GGE produced the same result for 28 of 40 (70%) individuals. When we assumed that all AB patients reported by Berkeley Heart Laboratory (GGE) could reasonably be reported as pattern A, the agreement between NMR and GGE improved to 32 of 40 (80%). Twenty persons (ϳ50%) were similarly classified by 3 of the 4 laboratories. Eight of these 20 individuals (ϳ40%) were classified as type A by the TGE, NMR, and GGE methods, whereas 10 of 20 (50%) were classified type B by NMR, VAP, and GGE. Two of 20 persons (10%) were classified as type B when TGE was 1 of the 3 methods.
The original basis for distinguishing the LDL phenotype among individuals was LDL particle size (9 ) . In 3 of the laboratory methods (TGE, GGE, and NMR), it was possible to determine the sizes of the main LDL particle fraction, providing the basis for LDL phenotypic classification, and in 1 case (GGE), 2 LDL particle sizes were given in the laboratory report, corresponding to LDL peaks 1 (GGE1) and 2 (GGE2). Total LDL-C could also be determined in 3 of the methods. Laboratory comparisons of LDL-C and particle size estimates are indicated in Fig. 2 .
We observed significant differences among methods for LDL-C concentration (Fig. 2A) . Although the absolute cholesterol concentrations were significantly different among methods, the within-subject LDL-C was relatively consistent (intraclass correlation ϭ 0.904). These results indicate a degree of bias within each method, but the relative LDL-C within individuals was maintained across methodologies. The distribution of LDL particle sizes among the methods is shown in Fig. 2B . Differences among the methods for estimated LDL particle sizes were also significant. Unlike the LDL-C concentration, the within-subject particle size estimates were not sustained across methods (intraclass correlation ϭ 0.246).
Discussion
Several clinical laboratories, including the 2 largest national clinical reference laboratories, now offer LDL subfraction analysis performed with different technologies. The consistency of patient classification among laboratories is unknown because there is no standardization among the different methods. To gain insight into the consistency of LDL phenotype classification, we sent a sample from each of 40 patients to 4 different laboratories that use different methods for LDL subfraction analysis.
In this comparison study, we focused on the diagnostic classification of patient LDL pattern type. Typically, individuals with large LDL particles are classified as type A, whereas individuals with small, dense LDL particles are classified as type B and are at a greater risk for CVD (9, 15 ) . Our results indicated only 3 of 39 patients (ϳ8%) were classified as having the same LDL phenotype by all 4 methods. The best agreement between 2 methods was between GGE and NMR (70%); this agreement may actually be Ͼ70%, as noted in the Results section. Removal of the 5 samples classified as AB, the 3 samples classified as not available (NA), and the 1 sample classified as indeterminate (IND) from the GGE report (Table 1) , leaves 31 samples for comparison. The betweenlaboratory agreement for these 31 samples for the GGE and NMR methods would have been 90% (28 of 31).
The inability to consistently classify patients did not seem to be dependent on the LDL particle per se, because the inconsistency in classification was more or less evenly distributed among the methods used, suggesting that the classification is method specific. The absolute LDL-C concentration was significantly different among the compared methods, but the within-subject reproducibility (intraclass correlation ϭ 0.904) was consistent across the methods. The LDL particle sizes were also significantly different among the methods, but unlike LDL-C, there was a poor correlation within individuals across methods. If the basis for patient classification is LDL particle size and if the particle size estimates for a given individual are different depending on the method used, then it is not surprising that patient classification across laboratories is not consistent.
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